Trials / Completed
CompletedNCT04281511
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 238 (actual)
- Sponsor
- National Cancer Center, Korea · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center. 2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
Detailed description
1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample 2. Collect data of Biomarker for pancreatic cancer 3. Compare with Big data and Cohort study in National cancer center 4. The number of subjects is changed by statistical consideration. 218-\>238
Conditions
Timeline
- Start date
- 2019-04-03
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2020-02-24
- Last updated
- 2023-11-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04281511. Inclusion in this directory is not an endorsement.